Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Thompson Investment Management Inc.

Thompson Investment Management Inc. lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.0% in the 1st quarter, Holdings Channel reports. The firm owned 7,625 shares of the company’s stock after selling 75 shares during the period. Thompson Investment Management Inc.’s holdings in Neurocrine Biosciences were worth $1,052,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vestal Point Capital LP purchased a new position in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $105,408,000. Los Angeles Capital Management LLC grew its stake in shares of Neurocrine Biosciences by 66.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock valued at $121,007,000 after buying an additional 364,986 shares during the period. Westfield Capital Management Co. LP increased its holdings in shares of Neurocrine Biosciences by 73.0% during the 3rd quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock worth $73,045,000 after buying an additional 273,952 shares during the last quarter. Norges Bank purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at approximately $35,731,000. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Neurocrine Biosciences by 59.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock valued at $77,892,000 after acquiring an additional 256,920 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NBIX has been the topic of a number of research analyst reports. Canaccord Genuity Group lifted their target price on Neurocrine Biosciences from $154.00 to $164.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Wedbush restated an “outperform” rating and issued a $152.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, May 29th. Citigroup increased their target price on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Oppenheimer increased their price objective on Neurocrine Biosciences from $200.00 to $216.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Six research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $152.00.

Insider Activity

In other news, Director Stephen A. Sherwin sold 40,000 shares of the stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total value of $5,338,400.00. Following the completion of the transaction, the director now owns 26,504 shares in the company, valued at approximately $3,537,223.84. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, Director Shalini Sharp sold 1,106 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $141.90, for a total value of $156,941.40. Following the sale, the director now directly owns 994 shares in the company, valued at approximately $141,048.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Stephen A. Sherwin sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the transaction, the director now owns 26,504 shares of the company’s stock, valued at approximately $3,537,223.84. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 88,697 shares of company stock worth $11,975,615. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Up 0.5 %

NASDAQ NBIX traded up $0.63 on Wednesday, hitting $135.71. The stock had a trading volume of 235,817 shares, compared to its average volume of 828,102. The company’s 50-day moving average is $137.14 and its two-hundred day moving average is $135.49. Neurocrine Biosciences, Inc. has a one year low of $93.02 and a one year high of $148.37. The stock has a market cap of $13.66 billion, a price-to-earnings ratio of 37.27 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The company had revenue of $515.30 million for the quarter, compared to analyst estimates of $512.21 million. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.